Posted by Michael Wonder on 21 Nov 2016
Consultation on CADTH’s proposed process for the assessment of companion diagnostics
21 November 2016 - CADTH is inviting stakeholder comments and feedback on the following proposed process for the assessment of companion diagnostics through the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs.
Companion diagnostics identify subgroups of patients for whom select drugs are likely to be most effective and safe. Based on feedback from participating jurisdictions, and guided by consultations with representatives internationally, across Canada, and among its committees, CADTH has developed a process for the assessment of companion diagnostics that is integrated into the CDR and pCODR programs. The proposed process would encompass companion diagnostics associated with drugs that are eligible for review under the CDR and pCODR programs. The objective of the proposed process is for CADTH to evaluate a submitted drug and its associated companion diagnostic together, rather than either one in isolation.
